SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
Astaxanthin (ASX) is highlighted as a promising supplement for treating hair loss due to its antioxidant properties. It may help with inflammation and oxidative stress, which are linked to hair loss and aging.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It humorously questions the idea of placing a biodome on the scalp.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
The conversation discusses using stemoxydine as a carrier for RU58841 and the search for affordable, premixed PG+E. Minoxidil is considered as an alternative, but simplicity is preferred.
The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
The conversation discusses hair loss and specific treatments like Minoxidil, Finasteride, and RU58841. It also highlights Procyanidin B-2 as a secret ingredient for hair growth.
The conversation is about experiences with Indian medications for hair loss, specifically using Finax (finasteride), Minopep Gold (minoxidil), and Biotin Plus tablets. Users discuss side effects like low libido and hair regrowth results, with some switching to different brands or dosages to manage side effects.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
The conversation discusses applying KX826 for hair loss without wasting it, with a suggestion to buzz the hair for easier application. The user considers using a 0.9% version after finding the 0.5% version insufficient.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.
The conversation discusses Peptonix microneedling, a copper peptide serum, as a potential hair loss treatment. Users compare it to finasteride and minoxidil, noting side effects and personal experiences with these treatments.
The user experienced hair regrowth using Koshine KX-826 after two months, noticing new baby hairs and reduced shedding, while continuing to use Hims spray. They reported no side effects from Koshine and plan to keep monitoring progress.
The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.